Department of Medicine, Division of Hematology/Oncology, Taichung Veterans General Hospital, 160, Section 3, Chungkang Road, Taichung 407, Taiwan.
World J Surg Oncol. 2012 Jul 16;10:150. doi: 10.1186/1477-7819-10-150.
Primary splenic diffuse large B-cell lymphoma (DLBCL) is a rare clinical condition, which is generally treated by six to eight cycles of chemotherapy involving a combination of rituximab and the cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP) regimen. However, the treatment for chemorefractory primary splenic DLBCL remains controversial. Therapeutic splenic irradiation (SI) might be a reasonable and possibly the only treatment option with curative intention for patients with chemorefractory primary splenic DLBCL. However, the efficacy and safety of therapeutic SI are unclear. Herein, we present the case of a primary splenic DLBCL patient who was refractory to multiple chemotherapy regimens but achieved complete remission after administration of therapeutic SI. However, his condition was complicated with severe gastric variceal bleeding due to splenic venous thrombosis, which was successfully treated via splenectomy and short gastric vein ligation. On the basis of our findings, we concluded that the splenic venous thrombosis-induced gastric variceal bleeding was a rare but life-threatening adverse effect of the therapeutic SI administered for primary splenic DLBCL. Surgical intervention involving splenectomy and short gastric vein ligation is mandatory and should be performed as soon as possible for such patients.
原发性脾脏弥漫性大 B 细胞淋巴瘤(DLBCL)是一种罕见的临床病症,通常采用六到八个周期的化疗来治疗,其中包括利妥昔单抗和环磷酰胺、阿霉素、长春新碱和泼尼松(CHOP)方案的组合。然而,对于化疗耐药的原发性脾脏 DLBCL 的治疗仍然存在争议。治疗性脾照射(SI)可能是一种合理的、可能是唯一具有治愈意图的治疗选择,适用于化疗耐药的原发性脾脏 DLBCL 患者。然而,治疗性 SI 的疗效和安全性尚不清楚。在此,我们报告了一例原发性脾脏 DLBCL 患者的病例,该患者对多种化疗方案均耐药,但接受治疗性 SI 后达到完全缓解。然而,他的病情因脾静脉血栓形成而并发严重胃静脉曲张出血,通过脾切除术和胃短静脉结扎术成功治疗。基于我们的发现,我们得出结论,脾静脉血栓形成引起的胃静脉曲张出血是治疗原发性脾脏 DLBCL 时 SI 治疗罕见但危及生命的不良反应。对于此类患者,强制性的手术干预包括脾切除术和胃短静脉结扎术,并且应尽快进行。